IGSC 20% infusion
TAK-664-3002
Phase 3 mab completed
Quick answer
IGSC 20% infusion for Primary Immunodeficiency Disease is a Phase 3 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Primary Immunodeficiency Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- completed